Cancer diagnostics and therapeutics company Microlin Bio sets terms for $25 million IPO

By Renaissance Capital,

Shutterstock photo

Microlin Bio, a development stage diagnostics and therapeutics company focusing on microRNA and its role in oncology, announced terms for its IPO on Friday. The New York, NY-based company plans to raise $25 million by offering 3.6 million shares at a price range of $6 to $8. At the midpoint of the proposed range, Microlin Bio would command a fully diluted market value of $54 million. Microlin Bio, which was founded in 2013, plans to list on the NASDAQ under the symbol MCLB. Sunrise Securities Corp. is the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: MCLB

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by